News from connect biopharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Jan, 2021, 13:00 GMT Connect Biopharma Establishes Scientific Advisory Board Comprised of Clinical Development and Program Indication Experts

Connect Biopharma, a global clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators...


12 Nov, 2020, 13:00 GMT Connect Biopharma Announces Appointment of Karen J. Wilson and Dr. Kleanthis G. Xanthopoulos to Board of Directors

Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the...


09 Nov, 2020, 13:00 GMT Connect Biopharma to Present at the Jefferies Virtual London Healthcare Conference on November 17, 2020

Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the...


29 Oct, 2020, 11:00 GMT Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Rapid, Early and Continuous Improvement in Patient Quality of Life and Atopic Dermatitis (AD) Symptoms

Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the...


22 Oct, 2020, 12:30 BST Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe Atopic Dermatitis (AD) at EADV Virtual Meeting

Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the...


24 Aug, 2020, 13:00 BST Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs

Connect Biopharma ("Connect"), a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating ...


20 Jul, 2020, 13:00 BST Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules,...


25 Feb, 2020, 13:00 GMT Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia

Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules...


08 Jan, 2020, 11:00 GMT Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201

Connect Biopharma, a clinical-stage biopharmaceutical company aimed at identifying potent and specific immune modulating molecules faster and more...


06 May, 2019, 10:00 BST Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201

Connect Biopharma today announced that it has successfully completed a phase 1 single ascending dose (SAD) study of its novel IL-4Rα antibody,...


02 Jan, 2019, 19:15 GMT Connect Biopharmaceuticals Completes $55 Million Series B Financing to Accelerate Clinical Development of Novel Immune Modulators

Connect Biopharmaceuticals, a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and ...